Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology.

Demırcı, Umut; Oflazoğlu, Utku; Kodaz, Hilmi; Çiltaş, Aydın; Kefeli, Umut; Akyol, Murat; Öztürk, Bayram; Geredeli, Çağlayan; Şeker, Mehmet; Cihan, Şener; Taştekin, Didem; Sevinç, Alper; Akıncı, Muhammed Bülent; Uysal, Mükremın; Taşköylü, Burcu Yapar; Duran, Ayşe Ocak; Yazici, O.; Karaoğlu, Aziz; Benekli, Mustafa; Büyükberber, Süleyman

doi:10.1200/jco.2014.32.15_suppl.e16094

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the analysis of patients included in the COU-AA-302 trial who received docetaxel after abiraterone, consistently with different retrospective series, seems to suggest that the benefit of second-line docetaxel is lower than that observed in patients who received it in first-line [ 53 , 54 ]. Preclinical and clinical data suggest a variable degree of cross-resistance of abiraterone with enzalutamide but also of ARSi with docetaxel [ 48 , 55 , 56 ]; cabazitaxel, on the other hand, retains its clinical activity in patients pretreated with both chemotherapy and ARSi [ 57 , 58 ]. Retrospective data also support the notion that patients with early progression on first-line ARSi show increased response rates and time to PSA progression after treatment with second-line chemotherapy compared to the alternative ARSi [ 59 ].…”

Section: Optimal Sequencing In Mhspc Nmcrpc and Mcrpcmentioning

confidence: 99%

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

Cattrini

España

Mennitto

et al. 2021

Cancers

View full text Add to dashboard Cite

The treatment landscape of advanced prostate cancer has completely changed during the last decades. Chemotherapy (docetaxel, cabazitaxel), androgen-receptor signaling inhibitors (ARSi) (abiraterone acetate, enzalutamide), and radium-223 have revolutionized the management of metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177–PSMA-617 is also going to become another treatment option for these patients. In addition, docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to primary tumor have demonstrated the ability to significantly prolong the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, apalutamide, enzalutamide, and darolutamide have recently provided impactful data in patients with nonmetastatic castration-resistant disease (nmCRPC). However, which is the best treatment sequence for patients with advanced prostate cancer? This comprehensive review aims at discussing the available literature data to identify the optimal sequencing approaches in patients with prostate cancer at different disease stages. Our work also highlights the potential impact of predictive biomarkers in treatment sequencing and exploring the role of specific agents (i.e., olaparib, rucaparib, talazoparib, niraparib, and ipatasertib) in biomarker-selected populations of patients with prostate cancer (i.e., those harboring alterations in DNA damage and response genes or PTEN).

show abstract